Capital Research Global Investors
DPLO

Capital Research Global Investors’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History

Capital Research Global Investors’s Portfolio DPLO Stock Details DPLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-878,616
Closed -$11.1M – 448
2016
Q4 		$11.1M Sell
878,616
-148,184
-14% -$2.76M ﹤0.01% 407
2016
Q3 		$28.8M Buy
+1,026,800
New +$34.5M 0.01% 358

Other funds holding DPLO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
HIM
Hermes Investment Management London Uk, United Kingdom $7.52B AUM 20.67% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors's DPLO Position: Q1 2017 in Review

Capital Research Global Investors sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q1 2017, closing a stake of 878,616 shares — an estimated $11.1M sold.

Capital Research Global Investors first reported a position in DPLO in Q3 2016 and held it in 2 quarters. The position peaked at $28.8M in Q3 2016. 155 funds tracked by Wall St. Rank hold DPLO as of Q1 2017.

  • Capital Research Global Investors reported no remaining DIPLOMAT PHARMACY, INC. position as of Q1 2017 after selling out during the quarter.
  • Capital Research Global Investors sold 878,616 DIPLOMAT PHARMACY, INC. shares in Q1 2017, an estimated $11.1M.
  • Capital Research Global Investors first reported a position in DIPLOMAT PHARMACY, INC. in Q3 2016 and held it in 2 quarters.
  • Capital Research Global Investors's DIPLOMAT PHARMACY, INC. position peaked at $28.8M in Q3 2016.
  • 155 funds tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q1 2017.

Based on Capital Research Global Investors's 13F filing for Q1 2017, filed 15 May 2017.